BOUT Fact Sheet: CapForce IBD Breakout Opportunities ETF
Share
$36.63
close, Nov 20, 2026
Over the year to Nov 19, 2026, BOUT returned +4.8% in total and charged 0.80% a year.
- 1-year total return
- +4.9%
- to Nov 20, 2026
- Expense ratio
- 0.80%
- a year
- Net flow, since Apr 2026
- $0
- monthly N-PORT basis to Jul 31, 2026
Growth of $10,000, 1 year
BOUT $10,483 +4.8% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−13.9%
3 months−17.4%
Year to date+0.9%
1 year+4.9%
3 years+22.5%
5 years−0.1%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Enliven Therapeutics Inc7.26%
Bicara Therapeutics Inc7.04%
US Bancorp6.92%
Travere Therapeutics Inc6.84%
Waste Management Inc6.66%
Interface Inc6.26%
UBS Group AG6.13%
Goldman Sachs Group Inc4.71%
Bank of America Corp4.63%
PNC Financial Services Group I4.60%
BOUT top ten by weight, 61.0% of the fund, of its 25 equity positions, from the holdings filed for Jul 31, 2026.
Facts
Equity fund · First traded Sep 13, 2018 · Benchmark Its own holdings, as of Jul 31, 2026